Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer.

Szczegóły
Abstrakt

Tytuł:: Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer.
Autorzy:: Huang H; Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, Department of Pharmacology, University of Texas Southwestern, Dallas, Texas.
Brekken RA; Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, Department of Pharmacology, University of Texas Southwestern, Dallas, Texas.
Źródło:: American journal of physiology. Cell physiology [Am J Physiol Cell Physiol] 2020 Aug 01; Vol. 319 (2), pp. C233-C243. Date of Electronic Publication: 2020 May 20.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: Bethesda, Md. : American Physiological Society,
MeSH Terms:: Adenocarcinoma/*genetics
Cancer-Associated Fibroblasts/*metabolism
Carcinoma, Pancreatic Ductal/*genetics
Pancreatic Neoplasms/*genetics
Adenocarcinoma/classification ; Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Cancer-Associated Fibroblasts/pathology ; Carcinoma, Pancreatic Ductal/classification ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/pathology ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Molecular Targeted Therapy ; Pancreatic Neoplasms/classification ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Single-Cell Analysis ; Tumor Microenvironment/genetics
References:: Clin Cancer Res. 2019 Apr 1;25(7):2194-2205. (PMID: 30385653)
Nat Cell Biol. 2012 Dec;14(12):1251-60. (PMID: 23143399)
. 2017 Nov;16(11):2473-2485. (PMID: 28864681)
Nat Commun. 2017 Jul 07;8:16031. (PMID: 28685754)
Kidney Int. 2000 Feb;57(2):476-86. (PMID: 10652024)
Br J Cancer. 2020 Feb;122(4):498-505. (PMID: 31857726)
Gastroenterology. 2019 May;156(7):2024-2040. (PMID: 30721664)
Clin Exp Immunol. 1995 Jul;101(1):172-6. (PMID: 7621585)
Front Immunol. 2018 Aug 13;9:1865. (PMID: 30150989)
Oncoimmunology. 2012 Oct 1;1(7):1135-1145. (PMID: 23170260)
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17892-7. (PMID: 19815530)
Cancer Cell. 2014 Jun 16;25(6):719-34. (PMID: 24856586)
Trends Cancer. 2019 Dec;5(12):789-798. (PMID: 31813456)
EBioMedicine. 2018 Oct;36:209-220. (PMID: 30243489)
JCI Insight. 2019 Jul 23;5:. (PMID: 31335328)
N Engl J Med. 2007 Dec 20;357(25):2543-51. (PMID: 18094375)
Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118472. (PMID: 30954569)
J Clin Invest. 2004 Aug;114(3):438-46. (PMID: 15286810)
Cancer Discov. 2019 Feb;9(2):282-301. (PMID: 30366930)
Cell Metab. 2019 Jan 8;29(1):141-155.e9. (PMID: 30174305)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Trends Cancer. 2018 Jun;4(6):418-428. (PMID: 29860986)
Cancers (Basel). 2015 Sep 29;7(4):1994-2011. (PMID: 26426054)
Cancer Res. 2004 Dec 1;64(23):8492-5. (PMID: 15574751)
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834)
Science. 2009 Jun 12;324(5933):1457-61. (PMID: 19460966)
Gut. 2018 Feb;67(2):320-332. (PMID: 27797936)
J Exp Med. 2014 Jul 28;211(8):1503-23. (PMID: 25071162)
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5112-6. (PMID: 3393534)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Semin Cancer Biol. 2014 Apr;25:15-22. (PMID: 24412104)
Blood. 2001 Oct 15;98(8):2396-402. (PMID: 11588036)
Proc Natl Acad Sci U S A. 2018 Feb 06;115(6):E1147-E1156. (PMID: 29351990)
Front Physiol. 2018 May 01;9:419. (PMID: 29765329)
Cancer Cell. 2014 Jun 16;25(6):735-47. (PMID: 24856585)
J Thorac Oncol. 2016 Sep;11(9):1482-92. (PMID: 27287412)
Oncotarget. 2017 Sep 11;8(44):76722-76739. (PMID: 29100344)
Gut. 2019 Jan;68(1):159-171. (PMID: 30177543)
Virchows Arch. 2002 Mar;440(3):298-303. (PMID: 11889601)
J Cell Sci. 2009 Sep 15;122(Pt 18):3209-13. (PMID: 19726630)
J Exp Med. 2017 Mar 6;214(3):579-596. (PMID: 28232471)
J Biol Chem. 2016 Oct 28;291(44):23208-23223. (PMID: 27605668)
N Engl J Med. 1986 Dec 25;315(26):1650-9. (PMID: 3537791)
J Immunol. 2008 May 1;180(9):5771-7. (PMID: 18424693)
Nat Cell Biol. 2017 Mar;19(3):224-237. (PMID: 28218910)
Cancer Res. 2014 Feb 15;74(4):1032-44. (PMID: 24346431)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Cancer Discov. 2019 Aug;9(8):1102-1123. (PMID: 31197017)
Cancer Sci. 2016 May;107(5):569-75. (PMID: 26918382)
Sci Transl Med. 2019 Jun 5;11(495):. (PMID: 31167927)
Int J Cancer. 2009 Feb 15;124(4):853-61. (PMID: 19035451)
Front Cell Dev Biol. 2019 Apr 24;7:60. (PMID: 31106200)
Cancer Res. 2008 Jun 1;68(11):4331-9. (PMID: 18519693)
Nat Med. 2016 May;22(5):497-505. (PMID: 27089513)
Stem Cells. 2010 Oct;28(10):1856-68. (PMID: 20734355)
Nat Rev Cardiol. 2018 Oct;15(10):631-647. (PMID: 29950578)
Kidney Int. 1998 Dec;54(6):2160-9. (PMID: 9853283)
Mol Cell. 1997 Dec;1(1):13-23. (PMID: 9659899)
Cancer Cell. 2018 Mar 12;33(3):463-479.e10. (PMID: 29455927)
Neoplasia. 2011 Aug;13(8):716-25. (PMID: 21847363)
Curr Protein Pept Sci. 2018;19(12):1138-1154. (PMID: 29150917)
PLoS One. 2013 May 16;8(5):e64566. (PMID: 23696899)
Cell Death Differ. 2016 Jan;23(1):132-45. (PMID: 26068592)
Oncogene. 2015 Sep 10;34(37):4821-33. (PMID: 25531323)
Cancer Res. 2005 Apr 15;65(8):3307-18. (PMID: 15833864)
Nat Rev Immunol. 2011 Jun;11(6):427-35. (PMID: 21597472)
Gastroenterology. 1998 Aug;115(2):421-32. (PMID: 9679048)
Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647)
J Clin Invest. 2012 Mar;122(3):899-910. (PMID: 22293174)
Cancer Res. 2019 Jan 15;79(2):328-330. (PMID: 30647067)
Clin Cancer Res. 2018 Dec 1;24(23):5883-5894. (PMID: 30082477)
Cancer Discov. 2020 Feb;10(2):232-253. (PMID: 31699795)
Cancer Immunol Immunother. 1996 Dec;43(5):262-8. (PMID: 9024502)
Trends Endocrinol Metab. 2015 Oct;26(10):515-523. (PMID: 26412153)
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4558-4566. (PMID: 30700545)
J Hematol Oncol. 2019 Aug 28;12(1):86. (PMID: 31462327)
Front Immunol. 2019 Aug 02;10:1835. (PMID: 31428105)
Nat Commun. 2015 Apr 02;6:6709. (PMID: 25833741)
J Biol Chem. 1999 Apr 30;274(18):12933-8. (PMID: 10212284)
J Clin Invest. 2007 Jan;117(1):50-9. (PMID: 17200706)
PLoS One. 2017 Jul 27;12(7):e0182039. (PMID: 28750018)
Cell Rep. 2014 Jun 12;7(5):1664-1678. (PMID: 24857661)
Cancer Res. 2013 May 15;73(10):3007-18. (PMID: 23514705)
Haematologica. 2009 Feb;94(2):258-63. (PMID: 19109217)
Nat Rev Drug Discov. 2017 Jan;16(1):35-52. (PMID: 27811929)
Cancers (Basel). 2018 Sep 06;10(9):. (PMID: 30200666)
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183. (PMID: 27028474)
PLoS One. 2013 Jul 26;8(7):e68923. (PMID: 23922669)
Nat Rev Cancer. 2016 Aug 23;16(9):582-98. (PMID: 27550820)
EMBO Mol Med. 2019 Nov 7;11(11):e10515. (PMID: 31609088)
Pancreas (Fairfax). 2019;3(1):e1-e4. (PMID: 32030361)
Sci Transl Med. 2018 Nov 28;10(469):. (PMID: 30487249)
PeerJ. 2018 Jun 14;6:e4928. (PMID: 29915688)
Trends Immunol. 2010 Jun;31(6):220-7. (PMID: 20538542)
Nat Genet. 2002 Nov;32(3):355-7. (PMID: 12379854)
Int Rev Cell Mol Biol. 2011;291:1-19. (PMID: 22017972)
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348. (PMID: 29717230)
Br J Cancer. 2013 Jan 15;108(1):1-8. (PMID: 23299539)
Clin Cancer Res. 2012 Aug 15;18(16):4266-76. (PMID: 22896693)
J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200. (PMID: 21123617)
Exp Cell Res. 2010 Oct 15;316(17):2713-22. (PMID: 20451516)
Postgrad Med J. 2009 Jan;85(999):9-14. (PMID: 19240282)
Cell. 2017 Dec 14;171(7):1611-1624.e24. (PMID: 29198524)
J Cell Biol. 2008 Mar 24;180(6):1277-89. (PMID: 18362184)
Dis Model Mech. 2018 Apr 19;11(4):. (PMID: 29686035)
Blood. 2013 Aug 15;122(7):1105-13. (PMID: 23757729)
Stem Cells Int. 2015;2015:628767. (PMID: 26273305)
Commun Biol. 2018 Oct 16;1:170. (PMID: 30345394)
J Clin Invest. 2002 Aug;110(3):341-50. (PMID: 12163453)
Nat Med. 2018 Aug;24(8):1277-1289. (PMID: 29988129)
Gastroenterology. 2013 Jun;144(6):1210-9. (PMID: 23622130)
J Exp Med. 2011 Mar 14;208(3):469-78. (PMID: 21339327)
Cardiovasc Res. 2005 Nov 1;68(2):307-17. (PMID: 15979058)
Pancreas. 2004 Oct;29(3):179-87. (PMID: 15367883)
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3091-100. (PMID: 25024225)
Cell Prolif. 2019 May;52(3):e12605. (PMID: 30945363)
Stem Cells. 2015 Nov;33(11):3197-204. (PMID: 26284340)
Int J Biochem Cell Biol. 2012 Nov;44(11):1800-12. (PMID: 22750474)
Curr Opin Cell Biol. 2006 Oct;18(5):516-23. (PMID: 16919435)
Nat Rev Mol Cell Biol. 2019 Aug;20(8):457-473. (PMID: 31182865)
Cancer Res. 2015 Mar 15;75(6):963-73. (PMID: 25600648)
J Clin Oncol. 2015 Dec 20;33(36):4284-92. (PMID: 26527777)
Cell Death Dis. 2014 Jun 19;5:e1295. (PMID: 24946088)
Am J Pathol. 1999 Oct;155(4):1087-95. (PMID: 10514391)
Grant Information:: U54 CA210181 United States CA NCI NIH HHS; CA192381 International HHS | NIH | National Cancer Institute (NCI)
Contributed Indexing:: Keywords: cancer-associated fibroblasts; fibroblast heterogeneity; pancreatic ductal adenocarcinoma
Entry Date(s):: Date Created: 20200521 Date Completed: 20201022 Latest Revision: 20210802
Update Code:: 20240105
PubMed Central ID:: PMC7500219
DOI:: 10.1152/ajpcell.00079.2020
PMID:: 32432930
: Czasopismo naukowe

Pancreatic ductal adenocarcinoma (PDA) is a devastating disease with a poor survival rate. It is resistant to therapy in part due to its unique tumor microenvironment, characterized by a desmoplastic reaction resulting in a dense stroma that constitutes a large fraction of the tumor volume. A major contributor to the desmoplastic reaction are cancer-associated fibroblasts (CAFs). CAFs actively interact with cancer cells and promote tumor progression by different mechanisms, including extracellular matrix deposition, remodeling, and secretion of tumor promoting factors, making CAFs an attractive target for PDA. However, emerging evidences indicate significant tumor-suppressive functions of CAFs, highlighting the complexity of CAF biology. CAFs were once considered as a uniform cell type within the cancer stroma. Recently, the existence of CAF heterogeneity in PDA has become appreciated. Due to advances in single cell technology, distinct subtypes of CAFs have been identified in PDA. Here we review recent updates in CAF biology in PDA, which may help develop effective CAF-targeted therapies in the future.

Informacja